Q-omics provides the consensus-scored MIR4796 profile across patient tissues and cancer cell-line models. MIR4796 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, MIR4796 is differentially expressed in 1, with the highest sampling consensus in LIHC. Additionally, MIR4796 RNA expression shows 10,870 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight READ, LIHC, and LUAD as cancer lineages where MIR4796 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4796 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4796 survival associations across molecular data types. MIR4796 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4796 RNA expression–survival associations across cancer types. High MIR4796 expression shows unfavorable associations in READ, UCS, DLBC, CESC and GBM, but favorable associations in KIRC. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for MIR4796 RNA expression.
This table summarizes MIR4796 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4796. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4796 shows higher tumor expression in LIHC. The LIHC box plot shows higher MIR4796 RNA expression in tumor versus normal tissue (log2 FC = +0.079, t-test p = .038).
This table shows molecular features associated with MIR4796 in patient tissues and cancer cell lines. In patient samples, MIR4796 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
